The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
To evaluate the adjuvant clinical use of [−2] precursor prostate-specific antigen ([−2]pPSA), which is associated with prostate cancer (PCa), and “benign” PSA, related to benign prostatic hyperplasia, in selecting a treatment strategy in patients with screen-detected PCa. Research-use immunoassays (Beckman Coulter) were used to measure [−2]pPSA, sum [−7, −5, −4, and −2]pPSA, and benign PSA from...
To evaluate whether the incidence of atrophy reported on sextant biopsies is associated with subsequent prostate cancer detection and to obtain a more thorough analysis of the different categories and extent of atrophy, we performed a review of benign biopsy cores. In the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer, 4117 and 1840 men underwent sextant biopsy...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.